Evidence map›Paper›PMID 41087534›Full record

ArticleScientific reports2025

Dynamic alterations of oral fungal microbiota in Omicron infected patients.

Yarong Ma, Shanshuo Liu, Guizhen Zhang, Liwen Liu, Junyi Sun, Yawen Zou, Ying Sun, Lei Li, Benchen Rao, Haiyu Wang and 2 more

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Yarong Ma *Department of Infectious Diseases, State Key Laboratory of Antiviral Drugs, Pingyuan Laboratory, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China.
Shanshuo Liu *Department of Infectious Diseases, State Key Laboratory of Antiviral Drugs, Pingyuan Laboratory, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China.
Guizhen ZhangDepartment of Infectious Diseases, State Key Laboratory of Antiviral Drugs, Pingyuan Laboratory, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China.
Liwen LiuDepartment of Infectious Diseases, State Key Laboratory of Antiviral Drugs, Pingyuan Laboratory, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China.
Junyi SunDepartment of Infectious Diseases, State Key Laboratory of Antiviral Drugs, Pingyuan Laboratory, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China.
Yawen ZouDepartment of Infectious Diseases, State Key Laboratory of Antiviral Drugs, Pingyuan Laboratory, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China.
Ying SunDepartment of Infectious Diseases, State Key Laboratory of Antiviral Drugs, Pingyuan Laboratory, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China.
Lei LiDepartment of Infectious Diseases, State Key Laboratory of Antiviral Drugs, Pingyuan Laboratory, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China.
Benchen RaoDepartment of Infectious Diseases, State Key Laboratory of Antiviral Drugs, Pingyuan Laboratory, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China.
Haiyu WangDepartment of Infectious Diseases, State Key Laboratory of Antiviral Drugs, Pingyuan Laboratory, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China.
Zujiang YuDepartment of Infectious Diseases, State Key Laboratory of Antiviral Drugs, Pingyuan Laboratory, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China. johnyuem@zzu.edu.cn.
Zhigang RenDepartment of Infectious Diseases, State Key Laboratory of Antiviral Drugs, Pingyuan Laboratory, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China. fccrenzg@zzu.edu.cn.

Funding

National Key Research and Development Program of China 2023YFC3043514the Postdoctoral Fellowship Program of China Postdoctoral Science Foundation under Grant GZC20232430the Scientific Research and Innovation Team of The First Affiliated Hospital of Zhengzhou University ZYCXTD2023002Young and Middle-aged Academic Leaders of Henan Provincial Health Commission HNSWJW-2022013
6 · The paper itself

Abstract

Oral fungal microbiota plays an important role in many diseases, however, the role of oral fungal microorganisms in the development of patients infected with Omicron has not been reported. A total of 963 tongue coating samples were prospectively included in this study, and finally 336 samples from patients infected Omicron variant (PIOV), 234 samples from recovered patients infected with Omicron (RP), 71 samples from patients infected original strain of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (PIOS), 299 samples from healthy controls (HC) completed internal transcribed spacer (ITS) sequencing after screening and quality control. By comparing the difference of oral fungal microorganisms between PIOV, RP and HC, we found that with the recovery of PIOV, their oral fungal microecological diversity increased gradually. Besides, at the species level, there were 24 oral fungal species such as Zanclospora_jonesii increased gradually, while there were 24 oral fungal species such as Saccharomyces_cerevisiae decreased gradually. In addition, by comparing PIOS and PIOV, we found that the alpha diversity of oral fungal microorganisms in PIOV was significantly lower than PIOS and the main species of the two groups were different. At the same time, we randomly divided PIOV and HC into training and validation set. Based on random forest model and five-fold cross-validation, we identified three optimal microbial markers of oral fungi and constructed a diagnostic model of PIOV. The area under the curve (AUC) value of PIOV group was 99.01% in discovery phase and 97.84% in verification phase. In summary, based on large-scale samples, this study is the first to elucidate the characteristics of oral fungal microbiota changes during PIOV recovery and establish a supplemental non-invasive diagnostic model for PIOV based on the oral fungal microbiome.

Indexed as

COVID-19FungiMicrobiotaMouthMycobiomeAdultAgedFemaleHumansMaleMiddle AgedProspective StudiesSARS-CoV-2TongueCOVID-19Diagnostic modelsDynamic alterationsOmicron variantOral fungiViral variation

Identifiers

PMID41087534
PMCPMC12521731

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.